These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Carcinoid tumors]. Tóth M; Prónai L; Németh AM; Tulassay Z Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867 [TBL] [Abstract][Full Text] [Related]
4. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy. Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018 [TBL] [Abstract][Full Text] [Related]
5. Complications of midgut carcinoid tumors and carcinoid syndrome. van der Horst-Schrivers AN; Wymenga AN; Links TP; Willemse PH; Kema IP; de Vries EG Neuroendocrinology; 2004; 80 Suppl 1():28-32. PubMed ID: 15477713 [TBL] [Abstract][Full Text] [Related]
6. Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors. Toth-Fejel S; Pommier RF Am J Surg; 2004 May; 187(5):575-9. PubMed ID: 15135668 [TBL] [Abstract][Full Text] [Related]
7. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up]. Igaz P; Rácz K; Tulassay Z Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114 [TBL] [Abstract][Full Text] [Related]
9. Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examples. Allen KR; Degg TJ; Anthoney DA; Fitzroy-Smith D Ann Clin Biochem; 2007 May; 44(Pt 3):300-7. PubMed ID: 17456301 [TBL] [Abstract][Full Text] [Related]
11. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646 [TBL] [Abstract][Full Text] [Related]
12. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Tormey WP; FitzGerald RJ Postgrad Med J; 1995 Sep; 71(839):542-5. PubMed ID: 7479466 [TBL] [Abstract][Full Text] [Related]
13. [Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors]. Bläker M; de Weerth A Z Gastroenterol; 2006 Sep; 44(9):1003-4. PubMed ID: 16981075 [No Abstract] [Full Text] [Related]
14. Primary carcinoid tumor of the bilateral testis associated with carcinoid syndrome. Son HY; Ra SW; Jeong JO; Koh EH; Lee HI; Koh JM; Kim WB; Park JY; Shong YK; Lee KU; Kim GS; Kim MS Int J Urol; 2004 Nov; 11(11):1041-3. PubMed ID: 15509216 [TBL] [Abstract][Full Text] [Related]
15. Chromogranin A as a determinant of midgut carcinoid tumour volume. Kölby L; Bernhardt P; Swärd C; Johanson V; Ahlman H; Forssell-Aronsson E; Stridsberg M; Wängberg B; Nilsson O Regul Pept; 2004 Aug; 120(1-3):269-73. PubMed ID: 15177946 [TBL] [Abstract][Full Text] [Related]
16. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Pirker RA; Pont J; Pöhnl R; Schütz W; Griesmacher A; Müller MM Clin Chem Lab Med; 1998 Nov; 36(11):837-40. PubMed ID: 9877088 [TBL] [Abstract][Full Text] [Related]
17. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Biesma B; Willemse PH; Mulder NH; Verschueren RC; Kema IP; de Bruijn HW; Postmus PE; Sleijfer DT; de Vries EG Br J Cancer; 1992 Nov; 66(5):850-5. PubMed ID: 1384643 [TBL] [Abstract][Full Text] [Related]
18. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). de Herder WW Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):705-15. PubMed ID: 16253895 [TBL] [Abstract][Full Text] [Related]